Recent Updates
Recently added Catalysts

Meningioma: 3 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-09-04

Competitors3in the clinic
Median market cap$14.7Buniverse median $1.20B
Allocated capital$2.5B$30.8B competing
Phase 3 or filed03 mid, 0 early
Pure plays0this indication only
Capital rank80/299crowding rank 62

Meningioma is a concentrated bet: only 3 US-listed developers are in the clinic, and the median one is worth $14.7B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

JAZZ carries 52% of the $30.8B competing here, more than the other 2 companies combined.

$2.5B of allocated capital sits in Meningioma, ranking it 80th of 299 indications by the money committed to it.

Companies developing drugs for Meningioma 3

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
JAZZJazz PharmaceuticalsJZP3507Phase 21$16.1BNo14 30 Sep 2026
EXELExelixisZanzalintinibPhase 21$14.7BNo11 3 Dec 2026
NTHINeOnc Technologies HoldingsNEO100Phase 21$124MNo3 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. JAZZ holds 52% of the $30.8B competing in this indication.

Why Meningioma is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Meningioma has 3 competitors and a median of $14.7B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Breast Cancer10 companies · $2.7B · median $288MKnife fightChronic Myelogenous Leukemia2 companies · $2.4B · median $3.0BConcentrated betPancreatic Cancer9 companies · $2.4B · median $371MKnife fightProstate Cancer6 companies · $2.7B · median $1.1BKnife fightNon-Squamous Non-Small Cell Lung Cancer1 company · $2.7B · median $13.7BUncontestedMelanoma4 companies · $2.3B · median $2.6BConcentrated betGastrointestinal Stromal Tumor3 companies · $2.3B · median $1.6BConcentrated betMetastatic Castration Resistant Prostate Cancer3 companies · $2.8B · median $4.0BConcentrated bet

Meningioma pipeline questions

Which biotech companies are developing drugs for Meningioma?

Jazz Pharmaceuticals (JAZZ, JZP3507, Phase 2); Exelixis (EXEL, Zanzalintinib, Phase 2); NeOnc Technologies Holdings (NTHI, NEO100, Phase 2). Those are the 3 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Meningioma.

How advanced is the Meningioma pipeline?

Of the 3 clinical-stage programmes in Meningioma, 0 are in Phase 3 or filed, 3 are in mid-stage development and 0 are in early-stage development.

Which company leads the Meningioma field?

JAZZ is the largest developer in Meningioma, holding 52% of the $30.8B of market capitalisation competing in the indication. The median competitor is worth $14.7B.

When is the next Meningioma catalyst?

The next dated catalyst in Meningioma is JAZZ on 30 Sep 2026. 3 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map